What is Fosanis?
Founded in 2017 by Dr. Gandolf Finke and Dr. Jan Simon Raue, Fosanis GmbH is dedicated to enhancing the lives of individuals affected by cancer through advanced digital technology. The company's flagship product, the AI-powered DTx Mika, was developed in collaboration with leading oncological research institutions and cancer centers, including the University of Leipzig Medical Center and Charité Berlin. Mika is a personalized digital therapeutic platform that combines AI-driven monitoring and coaching with scientifically validated methods and therapy management techniques. Notably, Mika was the first and remains the only 'digital health application' (DiGA) approved for all cancer patients in 2021, highlighting its clinical efficacy and regulatory success. The platform facilitates continuous tracking of patient-reported outcomes and distress levels through daily check-ins, offering personalized coaching and psycho-oncological interventions.
How much funding has Fosanis raised?
Fosanis has raised a total of $10.6M across 1 funding round:
Series A
$10.6M
Series A (2022): $10.6M with participation from Ship2B Ventures, Ananda Impact Ventures, and EquityPitcher
Key Investors in Fosanis
Ship2B Ventures
Ship2B Ventures is a venture capital firm focused on impact startups addressing social and environmental challenges. They invest in early-stage companies with a focus on systemic change and disruptive innovation.
Ananda Impact Ventures
Ananda Impact Ventures invests in innovative technologies aimed at creating a sustainable future, focusing on areas like decarbonization and healthcare. They support visionary founders driving impactful change.
EquityPitcher
EquityPitcher Ventures backs world-changing technologies and entrepreneurs with the potential for significant impact. They leverage an extensive industry network to support B2B tech startups.
What's next for Fosanis?
The recent major strategic investment signifies a critical juncture for Fosanis, likely enabling the company to scale its operations, expand its market reach, and further refine its AI-driven digital therapeutics. This capital infusion is expected to accelerate the integration of Mika into broader healthcare ecosystems, potentially forging new partnerships with research institutions and healthcare providers. Fosanis's focus on empowering cancer patients through technology, coupled with its approved DiGA status, positions it for significant growth in the rapidly evolving digital health and oncology markets. Future developments may include expanding Mika's therapeutic applications and enhancing its AI capabilities for more personalized patient support.
See full Fosanis company page
